Loading…
Makes and markets vitamins, minerals and supplements under the Jamieson brand, sold in Canada and abroad.
Makes and markets vitamins, minerals and supplements under the Jamieson brand, sold in Canada and abroad.
Owns its manufacturing in Canada, which lets it make branded products, private-label products for retailers and contract orders on the same plants, and sells branded products across grocery, drug and club stores. China is served through cross-border online channels and distributors. It bought Youtheory in 2019.
Moat: narrow (brand, distribution). Jamieson is Canada's best-known VMS brand with strong retail shelf space and export relationships.
Headquarters: Toronto, Canada · Founded: 1922 · Employees: 1,346
Size Jamieson Wellness (JWEL.TO) is a Canada Health Care company (Pharmaceuticals: Other) with a market value of $1.35B, the 216th largest of 420 Canada companies the cockpit tracks. Shares closed at C$45.64 on 6 Nov 2026.
Performance Over six months the shares gained 34.5%, against -9.0% for the median peer and +5.2% for the Canada market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 15.0% over the last twelve months (peer median +9.6%); the operating margin is 14.8% (peer median 15.6%).
Valuation It trades at 21.2× forward earnings against a peer median of 18.6× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.7 points above its cost of capital (7.6% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$881M | C$822M | C$734M | C$676M | C$547M |
| Revenue growth | — | +12% | +9% | +24% | — |
| Gross profit | C$369M | C$338M | C$276M | C$234M | C$198M |
| EBITDA | C$151M | C$133M | C$112M | C$108M | C$101M |
| Net income | C$78.6M | C$62.4M | C$51.9M | C$47.9M | C$52.8M |
| Free cash flow | C$23.1M | C$69.8M | C$52.4M | C$22.9M | C$36.7M |
| Capital expenditure | C$13.4M | C$13.6M | C$10.2M | C$9.31M | C$14.6M |
| Total debt | C$477M | C$445M | C$427M | C$460M | C$467M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jamieson Wellness JWEL.TO | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% |
| Church & Dwight CHD | $25.8B | +17% | +2% | 18% | 27.4× | 6.9% |
| By-health 300146.SZ | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JWEL.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | +0.4% | 11th highest of 21 |
| 6-month return | +34.5% | -9.0% | 5th highest of 21 |
| Distance from 52-week high | -0.5% | -24.2% | highest of 21 |
| Revenue growth (TTM) | +15.0% | +9.6% | 10th highest of 21 |
| Operating margin | 14.8% | 15.6% | 9th lowest of 20 |
| Forward P/E | 21.2× | 18.6× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 11.0% | 1.5% | 5th most demanding of 17 |
| Growth delivered (Del g) | +15.3% | +10.5% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | -4.2 pp | -9.9 pp | 5th most demanding of 17 |
| ROIC minus cost of capital | +1.7 pp | +2.8 pp | 7th lowest of 20 |
| EV / EBITDA | 15.9× | 18.2× | 5th cheapest of 11 |
| Net debt / EBITDA | 3.0× | -0.7× | 2nd most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |